Related Experiment Video
Updated: Jun 24, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Drug evaluation: vildagliptin-metformin single-tablet combination
Abd A Tahrani1, Milan K Piya, Anthony H Barnett
1NIHR Research Training Fellow, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, Birmingham Heartlands Hospital, Birmingham, B9 5SS, UK. a.a.tahrani@bham.ac.uk
Advances in Therapy
|March 17, 2009
Summary
Vildagliptin and metformin combination therapy effectively manages type 2 diabetes by targeting key defects. This dual-action treatment offers sustained glycemic control without significant hypoglycemia or weight gain.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
- Diabetes Mellitus Research
Background:
- Type 2 diabetes is characterized by insulin resistance and impaired incretin hormone function.
- Effective glycemic control requires addressing multiple pathophysiological defects.
- Incretin-based therapies, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, offer a targeted approach.
Purpose of the Study:
- To evaluate the efficacy and safety of a single-tablet combination of vildagliptin and metformin for type 2 diabetes.
- To assess the additive benefits of combining a DPP-4 inhibitor with metformin.
- To compare the combination therapy with other standard treatment regimens.
Main Methods:
- Clinical trials involving patients with type 2 diabetes treated with vildagliptin and metformin.
- Assessment of glycemic control through hemoglobin A1c (HbA1c) levels.
- Comparison with metformin monotherapy and other combination therapies (e.g., pioglitazone-metformin, glimepiride-metformin).
Main Results:
- The vildagliptin-metformin combination demonstrated additive and sustained reductions in HbA1c compared to metformin alone.
- Equivalent HbA1c reductions were observed when compared to pioglitazone-metformin and glimepiride-metformin.
- The combination therapy showed a similar incidence of adverse events to placebo plus metformin, with no significant risk of hypoglycemia or weight gain.
Conclusions:
- The single-tablet vildagliptin-metformin combination is an effective and safe second-line treatment for type 2 diabetes.
- This combination addresses key diabetes defects through complementary mechanisms of action.
- It aligns with emerging clinical guidelines for blood glucose control in type 2 diabetes management.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...